학술논문

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
Document Type
Article
Source
In: Leukemia. (Leukemia, April 2022, 36(4):1171-1175)
Subject
Language
English
ISSN
14765551
08876924